AldaveG, TejadaS, PayE, MarigilM, BejaranoB, IdoateMA, : Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic acid-guided surgery. Neurosurgery72:915–921, 2013
AldaveG, TejadaS, PayE, MarigilM, BejaranoB, IdoateMA, : Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic acid-guided surgery. Neurosurgery72:915–921, 2013)| false
EidelO, BurthS, NeumannJO, KieslichPJ, SahmF, JungkC, : Tumor infiltration in enhancing and non-enhancing parts of glioblastoma: a correlation with histopathology. PLoS One12:e0169292, 2017
EidelO, BurthS, NeumannJO, KieslichPJ, SahmF, JungkC, : Tumor infiltration in enhancing and non-enhancing parts of glioblastoma: a correlation with histopathology. PLoS One12:e0169292, 2017)| false
EsquenaziY, FriedmanE, LiuZ, ZhuJJ, HsuS, TandonN: The survival advantage of “supratotal” resection of glioblastoma using selective cortical mapping and the subpial technique. Neurosurgery81:275–288, 2017(Errata in Neurosurgery 81:404, 2017; Neurosurgery 81:1047, 2017)
EsquenaziY, FriedmanE, LiuZ, ZhuJJ, HsuS, TandonN: The survival advantage of “supratotal” resection of glioblastoma using selective cortical mapping and the subpial technique. Neurosurgery81:275–288, 2017(Errata in Neurosurgery 81:404, 2017; Neurosurgery 81:1047, 2017))| false
GlennCA, BakerCM, ConnerAK, BurksJD, BonneyPA, BriggsRG, : An examination of the role of supramaximal resection of temporal lobe glioblastoma multiforme. World Neurosurg114:e747–e755, 2018
GlennCA, BakerCM, ConnerAK, BurksJD, BonneyPA, BriggsRG, : An examination of the role of supramaximal resection of temporal lobe glioblastoma multiforme. World Neurosurg114:e747–e755, 2018)| false
KotrotsouA, ElakkadA, SunJ, ThomasGA, YangD, AbrolS, : Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome. J Neurooncol139:125–133, 2018
KotrotsouA, ElakkadA, SunJ, ThomasGA, YangD, AbrolS, : Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome. J Neurooncol139:125–133, 2018)| false
LiYM, SukiD, HessK, SawayaR: The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?J Neurosurg124:977–988, 2016
LiYM, SukiD, HessK, SawayaR: The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?J Neurosurg124:977–988, 2016)| false
RohTH, KangSG, MoonJH, SungKS, ParkHH, KimSH, : Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study. J Neurosurg[epub ahead of print March 1, 2019. DOI: 10.3171/2018.12.JNS182558]
RohTH, KangSG, MoonJH, SungKS, ParkHH, KimSH, : Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study. J Neurosurg[epub ahead of print March 1, 2019. DOI: 10.3171/2018.12.JNS182558])| false
StummerW, PichlmeierU, MeinelT, WiestlerOD, ZanellaF, ReulenHJ, : Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol7:392–401, 2006
StummerW, PichlmeierU, MeinelT, WiestlerOD, ZanellaF, ReulenHJ, : Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol7:392–401, 2006)| false
TaphoornMJ, StuppR, CoensC, OsobaD, KortmannR, van den BentMJ, : Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol6:937–944, 2005
TaphoornMJ, StuppR, CoensC, OsobaD, KortmannR, van den BentMJ, : Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol6:937–944, 2005)| false